source
- FDA issues draft guidance for electronic IDE submissions via eSTARThe U.S. Food and Drug Administration released draft guidance outlining how sponsors can submit investigational device exemption (IDE) applications using the electronic Submission Template and Reso…
- Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran failNovartis CEO Vas Narasimhan has insisted that the phase 3 fail for del-desiran is just a “bump” in the Swiss pharma’s wider plans for the drug, despite costing the company an estimated $1.9 billion.